Published in Cancer Res on July 01, 2007
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science (2014) 5.63
An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene (2009) 4.10
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell (2011) 3.88
Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci U S A (2007) 3.84
Suppression of lung adenocarcinoma progression by Nkx2-1. Nature (2011) 3.27
Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene (2008) 2.83
Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol Cell (2013) 2.05
Characterizing heterogeneous cellular responses to perturbations. Proc Natl Acad Sci U S A (2008) 2.03
Lung cancer cell lines as tools for biomedical discovery and research. J Natl Cancer Inst (2010) 1.92
DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers. Oncogene (2008) 1.63
Molecular biology of lung cancer: clinical implications. Clin Chest Med (2011) 1.47
Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer. PLoS Genet (2008) 1.39
Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma. PLoS Med (2010) 1.38
Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung. J Clin Invest (2012) 1.36
Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. PLoS Biol (2014) 1.34
Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin Cancer Res (2011) 1.33
Lung cancer cell lines: Useless artifacts or invaluable tools for medical science? Lung Cancer (2010) 1.30
EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. Br J Cancer (2013) 1.25
MYBPH, a transcriptional target of TTF-1, inhibits ROCK1, and reduces cell motility and metastasis. EMBO J (2011) 1.17
Tight junction proteins: from barrier to tumorigenesis. Cancer Lett (2013) 1.14
Pathogenesis of lung cancer signalling pathways: roadmap for therapies. Eur Respir J (2009) 1.10
Pulmonary adenocarcinoma: a renewed entity in 2011. Respirology (2012) 1.09
Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer. Proc Natl Acad Sci U S A (2009) 1.09
MicroRNA-33a mediates the regulation of high mobility group AT-hook 2 gene (HMGA2) by thyroid transcription factor 1 (TTF-1/NKX2-1). J Biol Chem (2013) 1.06
Genetic and biochemical alterations in non-small cell lung cancer. Biochem Res Int (2012) 1.05
MiR-365 regulates lung cancer and developmental gene thyroid transcription factor 1. Cell Cycle (2012) 1.03
An emerging place for lung cancer genomics in 2013. J Thorac Dis (2013) 1.02
Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. Genes Dev (2013) 1.00
Intersections between pulmonary development and disease. Am J Respir Crit Care Med (2011) 1.00
MicroRNAs and lung cancers: from pathogenesis to clinical implications. Front Med (2012) 1.00
Update in lung cancer 2007. Am J Respir Crit Care Med (2008) 1.00
Occludin is a direct target of thyroid transcription factor-1 (TTF-1/NKX2-1). J Biol Chem (2012) 0.99
Do all lung adenocarcinomas follow a stepwise progression? Lung Cancer (2011) 0.96
Genomics of lung cancer. Proc Am Thorac Soc (2009) 0.94
The complexity of thyroid transcription factor 1 with both pro- and anti-oncogenic activities. J Biol Chem (2013) 0.94
Genome-wide analyses of Nkx2-1 binding to transcriptional target genes uncover novel regulatory patterns conserved in lung development and tumors. PLoS One (2012) 0.93
[Morphological and molecular pathology of lung cancer]. Pathologe (2010) 0.90
The relationship between TTF-1 expression and EGFR mutations in lung adenocarcinomas. PLoS One (2014) 0.89
Secretoglobin 3A2/uteroglobin-related protein 1 is a novel marker for pulmonary carcinoma in mice and humans. Lung Cancer (2010) 0.88
Lung stem and progenitor cells in tissue homeostasis and disease. Curr Top Dev Biol (2014) 0.87
A Smad3 and TTF-1/NKX2-1 complex regulates Smad4-independent gene expression. Cell Res (2014) 0.87
Thyroid transcription factor-1 (TTF-1) gene: identification of ZBP-89, Sp1, and TTF-1 sites in the promoter and regulation by TNF-α in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol (2011) 0.85
Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors. Clin Cancer Res (2013) 0.84
Thyroid-specific transcription factors and their roles in thyroid cancer. J Thyroid Res (2011) 0.83
The 2011 IASLC/ATS/ERS pulmonary adenocarcinoma classification: a landmark in personalized medicine for lung cancer management. J Thorac Dis (2014) 0.81
Lineage factors and differentiation states in lung cancer progression. Oncogene (2015) 0.81
Lenalidomide induces apoptosis and alters gene expression in non-small cell lung cancer cells. Oncol Lett (2012) 0.80
Nkx2-1: a novel tumor biomarker of lung cancer. J Zhejiang Univ Sci B (2012) 0.79
Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung. Oncoscience (2014) 0.79
ErbB4 is an upstream regulator of TTF-1 fetal mouse lung type II cell development in vitro. Biochim Biophys Acta (2013) 0.78
Integrative Genomics Implicates EGFR as a Downstream Mediator in NKX2-1 Amplified Non-Small Cell Lung Cancer. PLoS One (2015) 0.76
Receptor tyrosine kinase-like orphan receptor 1, a target of NKX2-1/TTF-1 lineage-survival oncogene, inhibits apoptosis signal-regulating kinase 1-mediated pro-apoptotic signaling in lung adenocarcinoma. Cancer Sci (2016) 0.76
Interdependent TTF1 - ErbB4 interactions are critical for surfactant protein-B homeostasis in primary mouse lung alveolar type II cells. J Cell Commun Signal (2015) 0.76
Thyroid Transcription Factor 1 Reprograms Angiogenic Activities of Secretome. Sci Rep (2016) 0.75
Comparison of immunohistochemistry and mRNA in situ hybridization in detecting thyroid transcription factor-1 expression in non-small cell lung carcinomas tissue. Oncol Lett (2015) 0.75
Distinct Characteristics of Small Cell Lung Cancer Correlate With Central or Peripheral Origin: Subtyping Based on Location and Expression of Transcription Factor TTF-1. Medicine (Baltimore) (2015) 0.75
Identification of mutant genes with high-frequency, high-risk, and high-expression in lung adenocarcinoma. Thorac Cancer (2014) 0.75
KRAS mutation-positive bronchial surface epithelium (BSE)-type lung adenocarcinoma with strong expression of TTF-1: a case providing a further insight as for the role of TTF-1 in the oncogenesis. Int J Clin Exp Pathol (2015) 0.75
Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer. Cancer Sci (2017) 0.75
Identification of the SOX2 interactome by BioID reveals EP300 as a mediator of SOX2-dependent squamous differentiation and lung squamous cell carcinoma growth. Mol Cell Proteomics (2017) 0.75
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol (2009) 21.94
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res (2004) 18.86
A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res (2005) 10.46
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med (2010) 8.59
Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res (2004) 7.76
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol (2005) 5.63
Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet (2008) 5.08
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med (2012) 4.90
Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res (2006) 4.62
Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci (2005) 4.55
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res (2008) 4.30
Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res (2005) 3.98
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci (2007) 3.52
Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst (2002) 3.44
Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol (2004) 3.38
Propionibacterium acnes strain populations in the human skin microbiome associated with acne. J Invest Dermatol (2013) 3.32
The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res (2005) 3.11
Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations. J Thorac Oncol (2012) 3.10
A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201). J Thorac Oncol (2011) 2.78
let-7 regulates Dicer expression and constitutes a negative feedback loop. Carcinogenesis (2008) 2.75
Diagnostic utility of EUS-guided FNA in patients with gastric submucosal tumors. Gastrointest Endosc (2010) 2.67
Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS One (2008) 2.52
Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res (2005) 2.48
Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J (2009) 2.42
Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-versus-host disease as antigen-presenting cells. Blood (2009) 2.39
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc (2011) 2.39
Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol (2006) 2.37
Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Res (2007) 2.35
Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol (2011) 2.34
Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol (2009) 2.33
TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol (2002) 2.32
Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res (2008) 2.30
Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol (2004) 2.26
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet (2012) 2.26
MicroRNAs in biological processes and carcinogenesis. Carcinogenesis (2006) 2.14
Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001. J Thorac Oncol (2015) 2.12
Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster. Cancer Res (2008) 2.08
Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol (2011) 2.07
Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol (2003) 2.06
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res (2010) 2.05
Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study. J Thorac Oncol (2014) 2.04
Diameter and rigidity of multiwalled carbon nanotubes are critical factors in mesothelial injury and carcinogenesis. Proc Natl Acad Sci U S A (2011) 2.01
Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med (2012) 1.98
An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol (2014) 1.97
Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience. J Thorac Oncol (2010) 1.96
Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother (2010) 1.92
Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations. Nat Genet (2010) 1.90
Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol (2004) 1.89
Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res (2008) 1.88
Corticosteroids correct aberrant CFTR localization in the duct and regenerate acinar cells in autoimmune pancreatitis. Gastroenterology (2010) 1.86